Skip to main content
Premium Trial:

Request an Annual Quote

Life Tech Sues Bio-Rad for Infringing Protein-Production Patents

NEW YORK (GenomeWeb News) – Life Technologies has filed suit against Bio-Rad for allegedly infringing four patents that cover methods for protein production, according to court documents filed last week.

Life Technologies filed a complaint on Aug. 13 in the US District Court for the District of Delaware charging Bio-Rad with infringing four patents: US Patent Nos. 6,703,484; 7,223,566; 7,259,242; and 7,265,206. All four patents describe methods for producing polypeptides in bacterial host cells and are assigned to Life Technologies.

In the complaint, Life Tech claims that Bio-Rad's Precision Plus line of protein standards infringes one or more claims of the four patents. The allegedly infringing products include, but are not limited to, Bio-Rad's Precision Plus Dual Color Standards, Precision Plus Kaleidoscope Standards, and Precision Plus Protein WesternC Standards, according to the complaint.

The company is seeking a permanent injunction that will prevent Bio-Rad from marketing the products, triple damages because of Bio-Rad's "willful infringement," and attorneys' fees and other costs.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.